Inventiva Corp - IVA Forward Price-to-Revenue Multiple

Reliance on external contractors for drug production and testing drives current volatility, where the actual value is 15387.70. The forward revenue multiple visualizes these market fluctuations. The prospects for Inventiva S.A. (IVA) are based on the uniqueness of Lanifibranor for NASH therapy, yet the stock's success is directly tied to clinical trial results and strict control of operating expenses.

Inventiva - IVA Market Cap to Future Revenue Ratio (period 07/04/2022 - 11/13/2026)

Analytical breakdowns for Inventiva Corp (IVA)

- market price and analyst price targets:

Price Chart Inventiva|IVA - Broker Consensus Forecast

- issuer market value details:

Market Valuation Inventiva Corp|IVA - Total Company Value

- business book valuation details:

Book Value per Share Inventiva|IVA - Total Stockholders' Equity|Market Value to Book Value Ratio inventivapharma.com|IVA - Total Business Assets

- business debt structure and liquidity details:

- financial results and valuation multiples details:

IVA - Final Profit|Expected Profit Inventiva S.A.|IVA - Business Payback Period|Projected Price to Earnings Inventiva Pharma|IVA - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Inventiva Corp|IVA - Operating profit EBITDA|Net earnings per share for the last 12 months Inventiva|IVA - Net earnings per share for the last four quarters|Quarterly EPS earnings growth inventivapharma.com|IVA - Expected net earnings per share growth this year|Expected earnings per share growth for next year Inventiva S.A.

- revenue and sales details:

IVA - Company Revenue|Projected Sales Volume Inventiva|IVA - P/S Multiple|Price-to-Projected Revenue Ratio Inventiva Corp

Comprehensive company analysis:Inventiva (IVA)

Inventiva S.A. competes in the high-risk biotechnology sector, where business value is driven by future commercial success. The ratio of current market capitalization to expected revenue digitizes market hopes for the monetization of new drugs. This indicator measures the premium investors are willing to pay per unit of future sales, accounting for regulatory risks. The trend of the forward P/S multiple reflects the volatility of confidence in management ahead of the release of key clinical data.

Who Inventiva S.A. competes with

Price-to-Projected Revenue Ratio Arrowhead Pharmaceuticals, Inc. ARWR|MIRM: Market Cap to Projected Revenue|DVAX: Forward Price-to-Revenue Multiple|ABUS: Price-to-Projected Revenue Ratio|GYRE: Forward P/S Multiple|Market Cap to Future Revenue Ratio assemblybio.com (ASMB)|Price-to-Projected Revenue Ratio Galectin Therapeutics, Inc.|Market Cap to Projected Revenue GNFT (Genfit Corp)|Forward Price-to-Revenue Multiple DRRX (DURECT Corporation)|Price to Expected Revenue Ratio ALGS|Forward P/S Multiple BIVI (BioVie)|Market Cap to Expected Sales Ratio Galmed Pharmaceuticals Ltd (GLMD)|NDRA: Forward Price-to-Revenue Multiple|HEPA: Price-to-Projected Revenue Ratio